Cargando…
以维奈克拉为基础的方案治疗伴t（8;21）的急性髓系白血病12例疗效及安全性回顾性分析
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Editorial office of Chinese Journal of Hematology
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450551/ https://www.ncbi.nlm.nih.gov/pubmed/37550208 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.06.011 |
| _version_ | 1785095225895550976 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10450551 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Editorial office of Chinese Journal of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104505512023-08-26 以维奈克拉为基础的方案治疗伴t（8;21）的急性髓系白血病12例疗效及安全性回顾性分析 Zhonghua Xue Ye Xue Za Zhi 短篇论著 Editorial office of Chinese Journal of Hematology 2023-06 /pmc/articles/PMC10450551/ /pubmed/37550208 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.06.011 Text en 2023年版权归中华医学会所有 https://creativecommons.org/licenses/by/3.0/This work is licensed under a Creative Commons Attribution 3.0 License. |
| spellingShingle | 短篇论著 以维奈克拉为基础的方案治疗伴t（8;21）的急性髓系白血病12例疗效及安全性回顾性分析 |
| title | 以维奈克拉为基础的方案治疗伴t（8;21）的急性髓系白血病12例疗效及安全性回顾性分析 |
| title_full | 以维奈克拉为基础的方案治疗伴t（8;21）的急性髓系白血病12例疗效及安全性回顾性分析 |
| title_fullStr | 以维奈克拉为基础的方案治疗伴t（8;21）的急性髓系白血病12例疗效及安全性回顾性分析 |
| title_full_unstemmed | 以维奈克拉为基础的方案治疗伴t（8;21）的急性髓系白血病12例疗效及安全性回顾性分析 |
| title_short | 以维奈克拉为基础的方案治疗伴t（8;21）的急性髓系白血病12例疗效及安全性回顾性分析 |
| title_sort | 以维奈克拉为基础的方案治疗伴t（8;21）的急性髓系白血病12例疗效及安全性回顾性分析 |
| topic | 短篇论著 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450551/ https://www.ncbi.nlm.nih.gov/pubmed/37550208 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.06.011 |
| work_keys_str_mv | AT yǐwéinàikèlāwèijīchǔdefāngànzhìliáobànt821dejíxìngsuǐxìbáixuèbìng12lìliáoxiàojíānquánxìnghuígùxìngfēnxī AT yǐwéinàikèlāwèijīchǔdefāngànzhìliáobànt821dejíxìngsuǐxìbáixuèbìng12lìliáoxiàojíānquánxìnghuígùxìngfēnxī AT yǐwéinàikèlāwèijīchǔdefāngànzhìliáobànt821dejíxìngsuǐxìbáixuèbìng12lìliáoxiàojíānquánxìnghuígùxìngfēnxī AT yǐwéinàikèlāwèijīchǔdefāngànzhìliáobànt821dejíxìngsuǐxìbáixuèbìng12lìliáoxiàojíānquánxìnghuígùxìngfēnxī AT yǐwéinàikèlāwèijīchǔdefāngànzhìliáobànt821dejíxìngsuǐxìbáixuèbìng12lìliáoxiàojíānquánxìnghuígùxìngfēnxī AT yǐwéinàikèlāwèijīchǔdefāngànzhìliáobànt821dejíxìngsuǐxìbáixuèbìng12lìliáoxiàojíānquánxìnghuígùxìngfēnxī |